Abstract Search

ea0081p140 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Benderradji Hamza , Elise Vernotte , Ares Gustave Soto , Jean Philippe Woillez , Romain Perbet , Melodie-Anne Karnoub , Benoit Soudan , Arnaud Jannin , Assaker Richard , Luc Buee , Prevot Vincent , Claude-Alain Maurage , Pascal Pigny , Marie-Christine Vantyghem , Emilie Merlen , Cortet Rudelli Christine

Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and patients: This single-center retrospective study included 21 patients who were newly diagno...

0 shares

ea0022p383 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

Raverot Gerald , Sturm Nathalie , De Fraipont Florence , Caron Philippe , Muller Marie , Cortet-Rudelli Christine , Salenave Sylvie , Assaker Richard , Dufour Henry , Gaillard Stephan , Francois Patrick , Jouanneau Emmanuel , Bernier Michele , Figarella-Branger Dominique , Maurage Claude-Alain , Trouillas Jacqueline , Borson-Chazot Francoise , Brue Thierry

Context: To date ten publications reporting only 16 patients with pituitary aggressive tumors or carcinomas treated with temozolomide are available. Expression of O6-methylguanine-DNA-methyltranferase (MGMT), a DNA repair protein implicated in the resistance to temozolomide, was studied in only 10 out of these 16 patients. It has been suggested that low expression of MGMT could predict temozolomide efficacy.Objective: The aim of this st...

0 shares

Endocrine Abstracts

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

BiosciAbstracts